View Item 

Show simple item record

Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)
dc.contributor.authorZalupski, Mark M.en_US
dc.contributor.authorShields, Anthony F.en_US
dc.contributor.authorLoRusso, Patricia M.en_US
dc.contributor.authorPrakash, Sucharuen_US
dc.contributor.authorWozniak, Antoinetteen_US
dc.contributor.authorFlaherty, Lawrence E.en_US
dc.contributor.authorSands, Howarden_US
dc.contributor.authorParchment, Ralph E.en_US
dc.contributor.authorJasti, Bhaskaraen_US
dc.date.accessioned2006-09-11T15:48:56Z
dc.date.available2006-09-11T15:48:56Z
dc.date.issued2002-02en_US
dc.identifier.citationLoRusso, Patricia M.; Prakash, Sucharu; Wozniak, Antoinette; Flaherty, Lawrence; Zalupski, Mark; Shields, Anthony; Sands, Howard; Parchment, Ralph; Jasti, Bhaskara; (2002). "Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)." Investigational New Drugs 20(1): 63-71. <http://hdl.handle.net/2027.42/45222>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45222
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12003195&dopt=citationen_US
dc.description.abstractPurpose: 5-Fluoro-Pyrimidinone (5FP)is an oral pro-drug of 5-Fluorouracil(5FU), and is converted to 5FU by hepaticaldehyde oxidase. Preclinically, 5FPdemonstrated anti-tumor activity againstcolon 38 and P 388 leukemia models in mice. Using an accelerated titration trial designwith one patient cohorts and initial 100%escalations, a Phase I trial was conductedto determine the maximum tolerated dose(MTD) of 5FP and describe its toxicity andpharmacokinetic profile.en_US
dc.format.extent99452 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherDose Limiting Toxicityen_US
dc.subject.otherMaximum Tolerated Doseen_US
dc.subject.otherPharmacokinetics of 5-FPen_US
dc.titlePhase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)en_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, MI, USAen_US
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, MI, USAen_US
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, MI, USAen_US
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, MI, USAen_US
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, MI, USAen_US
dc.contributor.affiliationotherSupergen, San Ramon, CA, USAen_US
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, MI, USAen_US
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, MI, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid12003195en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45222/1/10637_2004_Article_390715.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1014430216434en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_390715.pdf
Size:
97.12KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.